Reuters logo
BRIEF-FDA grants fast track designation for Mesoblast's cell therapy in children with acute graft versus host disease
March 7, 2017 / 11:15 AM / 7 months ago

BRIEF-FDA grants fast track designation for Mesoblast's cell therapy in children with acute graft versus host disease

March 7 (Reuters) - Mesoblast Ltd

* FDA grants fast track designation for Mesoblast’s cell therapy in children with acute graft versus host disease

* Mesoblast Ltd - Enrollment in phase 3 trial is expected to complete mid-2017 with a top-line read out in 2H CY 2017 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below